In conclusion, decitabine sensitized chemotherapy and orchestrated with R-CHOP in TP53mut DLBCL via SUV39H1-H3K9me3-ERVs axis, underlines a new anti-tumor mechanism of decitabine through modulating histone methylation. This evidence concerns the gene SUV39H1 and diffuse large B-cell lymphoma.